Itraconazole (Orungal) in the treatment of mycotic infections in oncologic patients]

Clinical and microbiological activity of itraconazole (Orungal, solution for oral use, "Janssen-Cilag") for treatment of oncological patients with inhospital infections associated with candida was evaluated. The trial included 50 patients with oncological pathology of respiratory tract, as representatives of risk group for candida contamination. Two groups of patients were formed: when candida contamination was proved patients of the test group were treated by antifungal agent itraconazole (Orungal, "Janssen-Cilag"). Patients in control group were treated by fluconazole (Diflazon, "KRKA") according to standard therapy regime. When no clinical efficacy was achieved patients in both groups were treated by amphotericin B (Fungizone, "Bristol-Myers Squibb"). Clinical efficacy was demonstrated at 13 patients and microbiological efficacy (pathogen elimination) at 12 patient of 14 of itraconazole group. Clinical efficacy was demonstrated at 9 patients and microbiological efficacy at 7 of 11 patients of fluconazole group. Treatment with amphotericin B was effective at all 4 patients treated with this antibiotic, microbiological effect was demonstrated for 3 patients of the group. Frequency of side effects was significantly less in itraconazole group. The course price was also significantly lower at itraconazole group. All this data are important for elaboration of optimal pharmaco economic policy regarding inhospital infections at critical care units.